Kura Oncology (NASDAQ: KURA) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Kura Oncology to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
64.3% of Kura Oncology shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.8% of Kura Oncology shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Kura Oncology and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kura Oncology Competitors||884||3271||11759||235||2.70|
Kura Oncology currently has a consensus price target of $18.30, indicating a potential upside of 16.19%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.09%. Given Kura Oncology’s peers higher possible upside, analysts plainly believe Kura Oncology has less favorable growth aspects than its peers.
This table compares Kura Oncology and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kura Oncology Competitors||-5,226.85%||-213.68%||-38.94%|
Earnings and Valuation
This table compares Kura Oncology and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Kura Oncology||N/A||-$27.56 million||-10.16|
|Kura Oncology Competitors||$284.49 million||$34.10 million||67.35|
Kura Oncology’s peers have higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About Kura Oncology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
What are top analysts saying about Kura Oncology? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kura Oncology and related companies.